Low acylation stimulating protein levels are associated with cardiometabolic disorders-secondary to autoimmune activation?
OBJECTIVE
We investigated the possible association of serum acylation stimulating protein (ASP) with cardiometabolic disorders and the evidence of autoimmune activation.


METHODS
Population-based randomly selected 1024 participants were cross-sectionally and prospectively analyzed. ASP concentrations were measured with a validated ELISA kit. Correlations were sought separately in subjects with no cardiometabolic disorders (n=427) designated as "healthy."


RESULTS
ASP was positively correlated with total testosterone and inversely correlated with platelet activating factor (PAF), PAF-acetylhydrolase (AH), in each gender, and positively correlated in "healthy" men with lipoprotein [Lp](a) and apolipoprotein B. Correlations of ASP with PAF values ≥22 nmol/L were abolished, contrasted to a strongly inverse one in subjects with PAF <22 nmol/L. In linear regression analyses in the whole sample, ASP was inversely associated independently with PAF and PAF-AH and, in men, positively with Lp(a) and sex hormone-binding globulin. Prevalent and (at 2.0 years' follow-up) incident metabolic syndrome (MetS, n=393), diabetes (n=154), and coronary heart disease (CHD, n=171) were analyzed by sex-, age-, and Lp(a)-adjusted logistic regression, using tertiles of ASP and PAF. The lower two (<42 nmol/L) ASP tertiles were a risk factor in combined sexes for MetS and diabetes. In women, incident CHD was predicted by either reduced or elevated ASP tertiles.


CONCLUSIONS
Findings can be explained by the notion of operation of immune responses against both ASP and oxidized PAF-like lipids of Lp(a) to yield for "reduced" values and increased likelihood of cardiometabolic disorders.
Department of Cardiology Cerrahpaşa Medical Faculty, İstanbul University; İstanbul-Turkey. alt_onat@yahoo.com.tr.
Altan
A
Onat
Department of Cardiology, Faculty of Medicine, Trakya University; Edirne-Turkey.
Servet
S
Altay
Department of Cardiology, Faculty of Medicine, Dicle University; Diyarbakır-Turkey.
Murat
M
Yüksel
Department of Endocrinology and Metabolism, Faculty of Medicine, Atatu¨rk University; Erzurum-Turkey.
Yusuf
Y
Karadeniz
Department of Public Health, Cerrahpaşa Medical Faculty, İstanbul University; İstanbul-Turkey.
Günay
G
Can
Department of Cardiology, Cerrahpaşa Medical Faculty, İstanbul University; İstanbul-Turkey.
Hüsniye
H
Yüksel
Department of Biochemistry, Faculty of Medicine, İstanbul University; İstanbul-Turkey.
Evin
E
Ademoğlu
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000097:blood; D015551:Autoimmunity; D015926:Complement C3a / Q000378:metabolism*; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000453:epidemiology / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000453:epidemiology* / Q000276:immunology; D008875:Middle Aged; D015995:Prevalence; D011446:Prospective Studies; D014421:Turkey / Q000453:epidemiology
C044541:complement C3a, des-Arg-(77)-; D015926:Complement C3a; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; C526684:PLA2G7 protein, human